Clinical Trial Update: Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating stereotactic ablative radiotherapy (SABR) for comprehensive treatment of oligometastatic tumors is ongoing but not currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tumors

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Metastatic Tumors | Phase 2 | Status: ACTIVE_NOT_RECRUITING